| Id |
Subject |
Object |
Predicate |
Lexical cue |
| p1_all0 |
14-39 |
Intervention |
denotes |
chlortracycline treatment |
| p2_i0 |
14-39 |
Pharmacological |
denotes |
chlortracycline treatment |
| p1_all1 |
157-179 |
Population |
denotes |
Polish children SoA4.2 |
| p1_all2 |
506-533 |
Intervention |
denotes |
chlortetracycline treatment |
| p2_i1 |
506-533 |
Pharmacological |
denotes |
chlortetracycline treatment |
| p1_all3 |
539-551 |
Intervention |
denotes |
tetracycline |
| p2_i2 |
539-551 |
Pharmacological |
denotes |
tetracycline |
| p1_all4 |
552-659 |
Population |
denotes |
resistant population of Salmonella typhimurium DT104 and the commensal Escherichia coli population in pigs. |
| p2_o4 |
752-774 |
Physical |
denotes |
numbers of resistant S |
| p1_all5 |
752-776 |
Outcome |
denotes |
numbers of resistant S . |
| p1_all6 |
777-788 |
Intervention |
denotes |
typhimurium |
| p2_i3 |
777-794 |
Pharmacological |
denotes |
typhimurium DT104 |
| p2_o8 |
1047-1075 |
Physical |
denotes |
tetracycline resistance gene |
| p1_all7 |
1123-1167 |
Outcome |
denotes |
level of chlortetracycline in the pig faeces |
| p2_o9 |
1123-1167 |
Physical |
denotes |
level of chlortetracycline in the pig faeces |
| p2_i4 |
1321-1338 |
Pharmacological |
denotes |
chlortetracycline |
| p1_all8 |
1375-1415 |
Outcome |
denotes |
proportion of resistant enteric bacteria |
| p2_o10 |
1375-1415 |
Physical |
denotes |
proportion of resistant enteric bacteria |
| p1_all9 |
1830-1864 |
Outcome |
denotes |
prevalence of H. pylori resistance |
| p2_o13 |
1830-1864 |
Physical |
denotes |
prevalence of H. pylori resistance |
| p2_i5 |
1868-1882 |
Pharmacological |
denotes |
clarithromycin |
| p1_all10 |
1868-1913 |
Intervention |
denotes |
clarithromycin, metronidazole and amoxycillin |
| p2_i6 |
1884-1897 |
Pharmacological |
denotes |
metronidazole |
| p2_i7 |
1902-1913 |
Pharmacological |
denotes |
amoxycillin |
| p1_all11 |
1917-2022 |
Population |
denotes |
children prior to eradication therapy, and to detect mutations responsible for clarithromycin resistance. |
| p1_all12 |
2124-2156 |
Outcome |
denotes |
Susceptibility to antimicrobials |
| p1_all13 |
2363-2376 |
Intervention |
denotes |
metronidazole |
| p2_i8 |
2363-2376 |
Pharmacological |
denotes |
metronidazole |
| p1_all14 |
2413-2427 |
Intervention |
denotes |
clarithromycin |
| p2_i9 |
2413-2427 |
Pharmacological |
denotes |
clarithromycin |
| p2_i10 |
2535-2546 |
Pharmacological |
denotes |
amoxicillin |
| p1_all15 |
2535-2547 |
Intervention |
denotes |
amoxicillin. |
| p1_all16 |
2570-2584 |
Intervention |
denotes |
clarithromycin |
| p2_i11 |
2570-2584 |
Pharmacological |
denotes |
clarithromycin |
| p1_all17 |
2726-2749 |
Outcome |
denotes |
MICs of clarithromycin. |
| p2_i12 |
2734-2748 |
Pharmacological |
denotes |
clarithromycin |
| p2_o21 |
2788-2822 |
Physical |
denotes |
prevalence of H. pylori resistance |
| p1_all18 |
2826-2840 |
Intervention |
denotes |
clarithromycin |
| p2_i13 |
2826-2840 |
Pharmacological |
denotes |
clarithromycin |
| p1_all19 |
2844-2859 |
Population |
denotes |
Polish children |
| p1_all20 |
2985-2999 |
Intervention |
denotes |
clarithromycin |
| p2_i14 |
2985-2999 |
Pharmacological |
denotes |
clarithromycin |
| p1_all21 |
3003-3018 |
Population |
denotes |
children SoA4.3 |
| p1_all22 |
3066-3086 |
Intervention |
denotes |
clarithromycin (CLA) |
| p2_i15 |
3066-3086 |
Pharmacological |
denotes |
clarithromycin (CLA) |
| p1_all23 |
3230-3337 |
Population |
denotes |
Methods: Thirty-six resistant strains from children and 30 from adults were obtained from gastric biopsies. |
| p1_all24 |
3365-3368 |
Intervention |
denotes |
CLA |
| p2_i16 |
3365-3368 |
Pharmacological |
denotes |
CLA |
| p2_i17 |
3718-3731 |
Pharmacological |
denotes |
metronidazole |
| p2_i18 |
4062-4075 |
Pharmacological |
denotes |
metronidazole |
| p1_all25 |
4355-4519 |
Population |
denotes |
nine dyspeptic patients that had different Mtz susceptibilities (S and R) before and after therapy and mixed Mtz-S/R subpopulations that were separated were tested. |
| p1_all26 |
5413-5461 |
Population |
denotes |
Helicobacter pylori in the United Kingdom SoA4.5 |
| p2_i19 |
5610-5630 |
Pharmacological |
denotes |
clarithromycin (CLA) |
| p1_all27 |
5610-5654 |
Intervention |
denotes |
clarithromycin (CLA) and metronidazole (MTZ) |
| p2_i20 |
5635-5654 |
Pharmacological |
denotes |
metronidazole (MTZ) |
| p1_all28 |
5703-5774 |
Intervention |
denotes |
Adenine (A) to guanine (G) or A to cytosine (C) mutations at nucleotide |
| p2_o45 |
5900-5920 |
Physical |
denotes |
level CLA resistance |
| p1_all29 |
5999-6074 |
Population |
denotes |
One thousand one hundred and fifty-one UK isolates from routine endoscopies |
| p2_p0 |
6012-6023 |
Sample-size |
denotes |
one hundred |
| p1_all30 |
6109-6120 |
Intervention |
denotes |
CLA and MTZ |
| p2_i21 |
6117-6120 |
Pharmacological |
denotes |
MTZ |
| p2_o49 |
6415-6449 |
Physical |
denotes |
heterozygous for A2142G and A2143G |
| p1_all31 |
6451-6462 |
Outcome |
denotes |
No mutation |
| p1_all32 |
6532-6557 |
Outcome |
denotes |
High level CLA resistance |
| p2_o51 |
6532-6557 |
Physical |
denotes |
High level CLA resistance |
| p2_i22 |
6677-6680 |
Pharmacological |
denotes |
MTZ |
| p1_all33 |
6721-6741 |
Outcome |
denotes |
level CLA resistance |
| p1_all34 |
7558-7593 |
Intervention |
denotes |
macrolide antibiotic clarithromycin |
| p2_i23 |
7558-7593 |
Pharmacological |
denotes |
macrolide antibiotic clarithromycin |
| p1_all35 |
7705-7719 |
Intervention |
denotes |
clarithromycin |
| p2_i24 |
7705-7719 |
Pharmacological |
denotes |
clarithromycin |
| p2_i25 |
7764-7778 |
Pharmacological |
denotes |
Clarithromycin |
| p1_all36 |
7764-7789 |
Outcome |
denotes |
Clarithromycin resistance |
| p2_o62 |
7764-7789 |
Physical |
denotes |
Clarithromycin resistance |
| p1_all37 |
8772-8797 |
Outcome |
denotes |
Efficacy and tolerability |
| p2_o68 |
8772-8797 |
Other |
denotes |
Efficacy and tolerability |
| p1_all38 |
8811-8882 |
Intervention |
denotes |
triple macrolide-containing anti-Helicobacter pylori treatment regimens |
| p2_i26 |
8811-8882 |
Pharmacological |
denotes |
triple macrolide-containing anti-Helicobacter pylori treatment regimens |
